- Joined
- Mar 12, 2009
- Messages
- 13,160
- Points
- 0
GlaxoSmithKline to axe 4,000 jobs in US, Europe
AFP - Sunday, January 31
British pharmaceuticals giant GlaxoSmithKline is to cut up to 4,000 more jobs as it restructures its workforce and focuses increasingly on emerging markets, The Sunday Times reported.
LONDON (AFP) - – British pharmaceuticals giant GlaxoSmithKline is to cut up to 4,000 more jobs as it restructures its workforce and focuses increasingly on emerging markets, The Sunday Times reported.
The majority of the jobs will be lost in the United States and Europe, the newspaper said.
GSK, which employs just under 100,000 staff globally, is expected to reveal plans for the job cuts when it releases its annual results on Thursday, the report said.
Its Anglo-Swedish rival AstraZeneca announced on Thursday it plans to axe 8,000 more jobs worldwide by 2014, extending a cost-cutting drive despite soaring profits.
While GSK is still seeking to develop new drugs, it is increasingly turning to emerging markets to find growth.
This led to it recently cutting 2,000 sales jobs in the United States while adding 1,500 staff in China.
The big players in the global pharmaceuticals industry are seeing their profits squeezed as they reduce their reliance on top-selling blockbuster drugs, many of whose patents will soon expire.
AFP - Sunday, January 31
British pharmaceuticals giant GlaxoSmithKline is to cut up to 4,000 more jobs as it restructures its workforce and focuses increasingly on emerging markets, The Sunday Times reported.
LONDON (AFP) - – British pharmaceuticals giant GlaxoSmithKline is to cut up to 4,000 more jobs as it restructures its workforce and focuses increasingly on emerging markets, The Sunday Times reported.
The majority of the jobs will be lost in the United States and Europe, the newspaper said.
GSK, which employs just under 100,000 staff globally, is expected to reveal plans for the job cuts when it releases its annual results on Thursday, the report said.
Its Anglo-Swedish rival AstraZeneca announced on Thursday it plans to axe 8,000 more jobs worldwide by 2014, extending a cost-cutting drive despite soaring profits.
While GSK is still seeking to develop new drugs, it is increasingly turning to emerging markets to find growth.
This led to it recently cutting 2,000 sales jobs in the United States while adding 1,500 staff in China.
The big players in the global pharmaceuticals industry are seeing their profits squeezed as they reduce their reliance on top-selling blockbuster drugs, many of whose patents will soon expire.
